China Tian Yuan Healthcare Group Limited (0557) AI Stock Analysis

• Market Cap: HK$355.09M
• Dividend Yield: N/A
• Average Volume (3M): 7.60K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.60
• Revenue Growth: -43.78%
• EPS Growth: -118.13%
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 47
• Industry: Travel Lodging
• EPS (TTM): >-0.01
• Shares Outstanding: 398,979,520
• 10 Day Avg. Volume: 200
• 30 Day Avg. Volume: 7,600
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.00
• Price Target Upside: 12.36% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: HK$1.00 ▲(12.36% Upside)

The overall stock score is primarily influenced by the company's financial performance challenges, including declining revenues and persistent losses. While technical analysis shows some positive momentum, valuation concerns due to a negative P/E ratio and lack of dividend yield weigh heavily on the score. The absence of earnings call data and corporate events means these factors do not impact the score.

Positive Factors

Strong Equity Position

A strong equity position indicates a robust capital structure, providing the company with a solid foundation to weather financial challenges and invest in growth opportunities.

Positive Operating Cash Flow

Consistent positive operating cash flow suggests operational efficiency, enabling the company to fund its operations and invest in strategic initiatives without relying heavily on external financing.

Conservative Leverage

A low debt-to-equity ratio indicates conservative leverage, reducing financial risk and providing flexibility to pursue strategic opportunities without excessive debt burden.

Negative Factors

Declining Revenue

Ongoing revenue decline indicates challenges in market competitiveness and product demand, which could hinder long-term growth and profitability if not addressed.

Persistent Losses

Persistent losses reflect underlying profitability issues, which may limit the company's ability to reinvest in growth and innovation, affecting its competitive position.

Volatile Free Cash Flow

Volatile free cash flow suggests challenges in cash management, which can impact the company's ability to fund operations and strategic initiatives consistently.

China Tian Yuan Healthcare Group Limited Business Overview & Revenue Model

Company Description

China Tian Yuan Healthcare Group Limited (0557) is a healthcare company based in China, engaged primarily in the research, development, manufacturing, and distribution of pharmaceutical products and healthcare services. The company operates in various sectors including traditional Chinese medicine, modern pharmaceuticals, and health management services. Its core offerings encompass a wide range of medications, health supplements, and integrated healthcare solutions aimed at improving patient outcomes and promoting overall health.

How the Company Makes Money

China Tian Yuan Healthcare Group Limited generates revenue through multiple channels, primarily focusing on the sale of pharmaceutical products and healthcare services. The company earns a significant portion of its income by manufacturing and distributing prescription drugs and over-the-counter medications. Additionally, the company offers health management services, which include wellness programs and consultations that contribute to its revenue. Strategic partnerships with healthcare institutions and distributors further bolster its market reach and sales volume. The growing demand for healthcare products in China, driven by an aging population and increased health awareness, serves as a vital factor in enhancing the company's earnings.

China Tian Yuan Healthcare Group Limited Financial Statement Overview

Summary

China Tian Yuan Healthcare Group Limited is facing significant financial challenges, with declining revenues and persistent losses impacting profitability. Although the balance sheet shows a strong equity position, the cash flow improvements are overshadowed by volatility and past inefficiencies. The company needs strategic adjustments to improve profitability and leverage cash flow stability.

Income Statement

The company has seen a consistent decline in revenue over the years, with significant negative figures in EBIT and net income indicating ongoing profitability issues. Gross profit margin is high but overshadowed by persistent losses, suggesting challenges in controlling operating expenses.

Balance Sheet

The company's debt-to-equity ratio is relatively low, indicating conservative leverage. However, the significant decline in stockholders' equity due to consistent losses raises concerns. The equity ratio remains strong, showing a robust capital structure despite financial challenges.

Cash Flow

Positive operating cash flow in recent years is a positive sign, suggesting some operational efficiency. However, free cash flow has been volatile, and prior negative figures highlight potential issues in managing cash effectively. Improvement in free cash flow is notable but needs sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.32M	26.84M	45.23M	54.22M	94.59M	56.34M
Gross Profit	20.56M	14.91M	25.16M	34.83M	71.31M	37.57M
EBITDA	-18.25M	-27.22M	-15.79M	-27.10M	-2.89M	-102.72M
Net Income	-14.52M	-34.24M	-15.48M	-38.45M	-22.12M	-110.03M
Balance Sheet
Total Assets	290.70M	260.93M	302.95M	333.55M	376.40M	381.30M
Cash, Cash Equivalents and Short-Term Investments	25.25M	27.05M	26.73M	31.60M	77.89M	71.08M
Total Debt	42.31M	40.93M	45.91M	51.13M	59.66M	55.06M
Total Liabilities	83.91M	84.98M	87.77M	91.52M	92.35M	83.91M
Stockholders Equity	224.46M	194.68M	230.26M	224.30M	256.25M	267.53M
Cash Flow
Free Cash Flow	24.14M	10.67M	4.51M	-31.71M	14.86M	49.20M
Operating Cash Flow	24.74M	10.69M	5.10M	-30.36M	16.32M	49.54M
Investing Cash Flow	364.00K	-3.00K	364.00K	-1.23M	-1.42M	-11.22M
Financing Cash Flow	-8.16M	-10.85M	-8.77M	-12.49M	-7.22M	-2.54M

China Tian Yuan Healthcare Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0557, the sentiment is Positive. The current price of 0.89 is above the 20-day moving average (MA) of 0.82, above the 50-day MA of 0.82, and above the 200-day MA of 0.68, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 64.95 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0557.

China Tian Yuan Healthcare Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0617	53 Neutral	HK$362.24M	―	-19.01%	―	-2.75%	-17.31%
Sector *	51 Neutral	$7.92B	-0.36	-43.38%	2.24%	22.38%	-2.16%
0199	51 Neutral	HK$198.68M	―	-31.95%	―	180.75%	-26.19%
0557	49 Neutral	HK$355.09M	―	-15.15%	―	-43.78%	-118.13%
0219	46 Neutral	HK$301.85M	―	-4.72%	―	3.58%	-91.61%
CQA2	―	€39.63M	―	-16.35%	―	―	―
RH6B	―	€63.01M	―	-28.68%	―	―	―

China Tian Yuan Healthcare Group Limited Corporate Events

China Tian Yuan Healthcare Group Announces Capital Injections and Shareholder Loan

China Tian Yuan Healthcare Group Limited announced capital injections and a shareholder loan involving its subsidiaries, Hengqin Hanyuemei and Shanghai Rifu, and a third party, Shanghai Huaman. The capital injections will increase Shanghai Rifu’s registered capital significantly, while the shareholder loan will provide additional financial support. These transactions, which are part of a series of agreements with Shanghai Huaman, are subject to disclosure requirements under Hong Kong’s listing rules due to their size.

China Tian Yuan Healthcare Group Secures Unanimous Shareholder Approval at AGM

China Tian Yuan Healthcare Group Limited announced that all resolutions proposed at their Annual General Meeting on June 27, 2025, were unanimously approved by shareholders. These resolutions included the re-election of directors, authorization of directors’ remuneration, reappointment of auditors, and granting of general mandates for issuing and repurchasing shares, indicating strong shareholder support and stability in the company’s governance and operational strategies.

China Tian Yuan Healthcare Group Announces 36th Annual General Meeting

China Tian Yuan Healthcare Group Limited has announced its thirty-sixth annual general meeting to be held on June 27, 2025, in Hong Kong. Key agenda items include the re-election of directors, approval of directors’ remuneration, and the re-appointment of auditors. Additionally, the company seeks approval to allot and issue additional shares, which could impact its capital structure and shareholder value.